Full CoverageNovo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
By Annika Kim Constantino
Top news
Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup
By Peter Loftus & Robb M. Stewart
Novo Exits Hims Partnership, Citing Concerns Over Compounded Drugs
By Naomi Kresge & Madison Muller
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
All coverage
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
By Stine Jacobsen & Amina Niasse
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
By Steve Gelsi
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
By Mary Cunningham
Hims Crashes After Novo Unexpectedly Yanks Collaboration Deal
By Allison Gatlin
Novo Nordisk dropping Hims could boost other GLP-1 providers
By Katherine Davis
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
By Josh Nathan-kazis & Mackenzie Tatananni
Novo sends Hims packing
By Bryce Elder
Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff’ Wegovy
By Grace Snelling
Novo abruptly ends obesity drug deal with Hims
By Jonathan Gardner
Novo Nordisk ends partnership with Hims & Hers over Wegovy copycats
By Nathaniel Weixel
Wegovy Maker Novo Nordisk Dumps Hims & Hers Relationship Over Claims of Deceptive Marketing
By Luke Funk
HIMS INVESTIGATION ALERT: Investigation Launched into Hims & Hers Health, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
By Robbins Geller Rudman
Why Hims & Hers Health Stock Is Crashing Today
By Johnny Rice
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
By Patrick Temple-West & Michael Peel
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
By Anjalee Khemlani
Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?
By Wajeeh Khan
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
By Allison Gatlin
Hims & Hers on track for biggest drop ever after Novo Nordisk ends partnership
By J. Edward Moreno Del Angel
Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade
Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices
By Aaron McDade